AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

AIM ImmunoTech (NYSE American: AIM) entered definitive agreements for a registered direct offering and concurrent private placement priced at-the-market for approximately $2.65 million in gross proceeds.

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) entered definitive agreements for a registered direct offering and concurrent private placement priced at-the-market for approximately $2.65 million in gross proceeds.

The company will issue 2,554,119 registered shares, 2,554,119 unregistered shares or pre-funded warrants, and Class J warrants for up to 10,216,476 shares to fund clinical manufacturing, current and planned Phase 3 trials, and working capital.

Positive

• $2.65 million gross proceeds from at-the-market equity financing
• Proceeds allocated to manufacture of clinical drug supply
• Funding supports current clinical trial activities
• Financing earmarked for planned Phase 3 clinical trial activities
• Additional capital for general working capital needs

Negative

• New issuance of 2,554,119 registered shares increases share count
• Concurrent issuance of 2,554,119 unregistered shares or pre-funded warrants adds equity supply
• Class J warrants for up to 10,216,476 shares may create future dilution

Argus Jun 9 session

-22.34% close to close Open Argus

Details

News Market Reaction – AIM

On Jun 9, the day this news came out, AIM closed 22.34% below the previous close.

Data tracked by StockTitan Argus for the Jun 9 session.

Key Figures

Gross proceeds: $2.65 million Registered shares: 2,554,119 shares Offering price: $0.5189 per share +5 more

Gross proceeds

$2.65 million

Registered direct offering and concurrent private placement

Registered shares

2,554,119 shares

Common stock in registered direct offering

Offering price

$0.5189 per share

Purchase price for Registered Shares

Unregistered shares

2,554,119 shares

Unregistered shares or pre-funded warrants in private placement

Class J warrant shares

10,216,476 shares

Underlying shares for Class J Warrants

Class J exercise price

$0.5189 per share

Exercise price of Class J Warrants

Warrant term

5 years

Expiration from initial exercise date for Class J Warrants

Expected closing date

June 10, 2026

Expected closing of offering, subject to conditions

Historical Context

5 past events · Latest: Jun 08

5 events

1. Jun 08

   Clinical progress update

   24h Move

   +13.1%

   Reported positive mid-year interim Phase 2 DURIPANC clinical progress for Ampligen combo.

2. Jun 04

   Investor communications

   24h Move

   -19.2%

   Released Virtual Investor video discussing Ampligen’s potential in Ebola preparedness.

3. Jun 01

   Trial enrollment milestone

   24h Move

   +120.3%

   Completed Phase 2 DURIPANC enrollment ahead of schedule with clear milestone timelines.

4. May 20

   Equity financing

   24h Move

   +5.7%

   Announced $2.4M registered direct and private placement with five-year Series I warrants.

5. May 19

   Balance sheet update

   24h Move

   +0.7%

   Reported major increase in stockholder equity and extension of key promissory note.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

registered direct offering, private placement, at-the-market, pre-funded warrants, +4 more

8 terms

registered direct offering financial

"entered into definitive agreements for a registered direct offering and concurrent private placement"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

private placement financial

"registered direct offering and concurrent private placement priced at-the-market"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

at-the-market financial

"registered direct offering and concurrent private placement priced at-the-market under NYSE American rules"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

pre-funded warrants financial

"unregistered shares of Common Stock (or pre-funded warrants in lieu thereof)"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

warrants financial

"unregistered Class J warrants (the “Class J Warrants”) to purchase up to 10,216,476 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

shelf registration statement regulatory

"takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-286319)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"the Company’s shelf registration statement on Form S-3 (File No. 333-286319)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

regulation d regulatory

"in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

OCALA, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of approximately $2.65 million, before deducting placement agent commissions and other offering expenses.

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

The offering is expected to close on or about June 10, 2026, subject to the satisfaction of customary closing conditions.

In the registered direct offering, the Company will issue and sell 2,554,119 shares of common stock, par value $0.001, at a purchase price of $0.5189 per share (the “Registered Shares”). In addition, in a concurrent private placement, the Company will issue and sell an aggregate of 2,554,119 unregistered shares of Common Stock (or pre-funded warrants in lieu thereof) (the “Unregistered Shares”) at the per share purchase price and unregistered Class J warrants (the “Class J Warrants”) to purchase up to 10,216,476 shares of Common Stock. The Class J Warrants will have an exercise price of $0.5189 per share, will be exercisable subject to stockholder approval and will expire five (5) years from the initial exercise date.

The Company intends to use the net proceeds from the offering for (i) the manufacture of clinical drug supply, (ii) the Company’s current clinical trial activities, (iii) the Company’s planned Phase 3 clinical trial activities, and (iv) working capital purposes.

The Registered Shares (or common stock equivalents in lieu thereof) are being offered and sold pursuant to a prospectus supplement to be filed with the Securities and Exchange Commission (“SEC”) in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-286319), which was declared effective by the SEC on July 3, 2025. The offering is being made only by means of a prospectus supplement and accompanying prospectus which are a part of the effective registration statement. The Unregistered Shares and Class J Warrants will be issued in a concurrent private placement. A prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, NY 10019, by phone at (212) 409-2000, or by email at prospectus@ladenburg.com. The private placement of the Unregistered Shares, the Class J Warrants and the shares underlying the Class J Warrants offered to the institutional investors will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 to the extent available. Forward-looking statements include all statements other than statements of historical fact and may be identified by words such as “believes,” “expects,” “intends,” “may,” “will,” “plans,” “potential,” “anticipates,” “estimates,” “continues,” “could,” “should” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include, without limitation, statements regarding the offering, the expected gross proceeds and anticipated closing of the offering, the intended use of proceeds, the issuance and terms of the Class J Warrants, anticipated milestones, the timing of commencement, enrollment, completion and results of clinical trials, the Company’s clinical and operational priorities, intellectual property expansion, regulatory progress and the timing and receipt of government approvals, if at all.

These forward-looking statements are based on the Company’s current expectations, estimates, forecasts and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks related to the satisfaction of closing conditions, market conditions, the availability and sufficiency of funding and clinical drug supply, the Company’s ability to conduct and complete planned clinical trials, the timing and results of preclinical studies and clinical trials, whether preliminary or preclinical results will be predictive of future clinical trial results or results in humans, the need for and receipt of regulatory approvals, changes in priorities at institutions sponsoring or conducting trials, the Company’s ability to protect and enforce its intellectual property rights, risks associated with potential foreign operations and other risks described in the Company’s filings with the SEC.

The Company is in various stages of determining whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers and immune-deficiency disorders, and significant additional testing and trials will be required to determine whether Ampligen® will be effective for these conditions. No assurance can be given that any current or planned clinical trials will be initiated, completed, successful or yield favorable or useful data, that preliminary studies will prove accurate or that future studies will not result in findings that differ from those previously reported by the Company. For a further discussion of risks and uncertainties, please review the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the SEC, including any prospectus supplement filed in connection with the offering and the documents incorporated by reference therein. These filings are available at www.sec.gov and www.aimimmuno.com. The information on the Company’s website is not incorporated by reference into this press release and is included for reference purposes only. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What financing did AIM ImmunoTech (NYSE American: AIM) announce on June 9, 2026?

AIM ImmunoTech announced a registered direct offering and concurrent private placement raising about $2.65 million in gross proceeds. According to AIM ImmunoTech, the financing is priced at-the-market under NYSE American rules and includes common shares, pre-funded warrants, and Class J warrants.

How many AIM ImmunoTech (AIM) shares are being issued in the June 2026 offering?

AIM ImmunoTech plans to issue 2,554,119 registered common shares and 2,554,119 unregistered shares or pre-funded warrants. According to AIM ImmunoTech, investors will also receive Class J warrants exercisable for up to 10,216,476 additional common shares, subject to stockholder approval.

What is the pricing and exercise price for AIM ImmunoTech’s June 2026 financing?

Both the common shares and pre-funded warrants are priced at $0.5189 per share. According to AIM ImmunoTech, the Class J warrants also carry a $0.5189 exercise price, are exercisable after stockholder approval, and will expire five years from their initial exercise date.

How will AIM ImmunoTech use the $2.65 million raised in its June 2026 offering?

AIM ImmunoTech intends to use net proceeds to fund clinical drug manufacturing and trial activities. According to AIM ImmunoTech, the capital will support current clinical trials, planned Phase 3 clinical trial activities, and general working capital requirements.

When is AIM ImmunoTech’s June 2026 registered direct offering expected to close?

The registered direct offering is expected to close on or about June 10, 2026, subject to customary conditions. According to AIM ImmunoTech, Ladenburg Thalmann is acting as exclusive placement agent for both the registered offering and concurrent private placement.

What are the key terms of AIM ImmunoTech’s Class J warrants issued in June 2026?

The Class J warrants allow investors to purchase up to 10,216,476 AIM common shares at $0.5189 each. According to AIM ImmunoTech, these warrants become exercisable upon stockholder approval and will remain exercisable for five years from the initial exercise date.

How is AIM ImmunoTech’s June 2026 private placement structured under U.S. securities laws?

The private placement of unregistered shares, pre-funded warrants, and Class J warrants relies on Section 4(a)(2) and Regulation D exemptions. According to AIM ImmunoTech, these securities cannot be offered or sold publicly without an effective registration statement or a valid exemption.